RhumbLine Advisers’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$505K Sell
407,147
-31,628
-7% -$39.2K ﹤0.01% 2678
2025
Q1
$518K Buy
438,775
+20,153
+5% +$23.8K ﹤0.01% 2561
2024
Q4
$766K Buy
418,622
+5,722
+1% +$10.5K ﹤0.01% 2390
2024
Q3
$702K Sell
412,900
-23,968
-5% -$40.7K ﹤0.01% 2478
2024
Q2
$598K Buy
436,868
+51,727
+13% +$70.9K ﹤0.01% 2547
2024
Q1
$1.44M Buy
385,141
+1,823
+0.5% +$6.84K ﹤0.01% 2072
2023
Q4
$3.76M Buy
383,318
+334
+0.1% +$3.28K ﹤0.01% 1584
2023
Q3
$3.2M Buy
382,984
+1,393
+0.4% +$11.6K ﹤0.01% 1601
2023
Q2
$5.08M Sell
381,591
-21,914
-5% -$291K 0.01% 1361
2023
Q1
$4.67M Buy
403,505
+44,460
+12% +$515K 0.01% 1363
2022
Q4
$2.94M Buy
359,045
+6,237
+2% +$51K ﹤0.01% 1587
2022
Q3
$2.05M Buy
352,808
+23,329
+7% +$135K ﹤0.01% 1746
2022
Q2
$1.46M Buy
329,479
+92,677
+39% +$410K ﹤0.01% 1940
2022
Q1
$2.16M Sell
236,802
-8,272
-3% -$75.3K ﹤0.01% 1779
2021
Q4
$5.01M Sell
245,074
-3,129
-1% -$64K 0.01% 1355
2021
Q3
$6.34M Sell
248,203
-1,568
-0.6% -$40.1K 0.01% 1211
2021
Q2
$8.73M Buy
249,771
+34,330
+16% +$1.2M 0.01% 1094
2021
Q1
$7.18M Sell
215,441
-8,546
-4% -$285K 0.01% 1202
2020
Q4
$5.81M Buy
223,987
+27,588
+14% +$716K 0.01% 1270
2020
Q3
$1.94M Sell
196,399
-15,083
-7% -$149K ﹤0.01% 1697
2020
Q2
$730K Buy
211,482
+17,121
+9% +$59.1K ﹤0.01% 2178
2020
Q1
$595K Sell
194,361
-7,119
-4% -$21.8K ﹤0.01% 2103
2019
Q4
$1.04M Buy
201,480
+3,203
+2% +$16.5K ﹤0.01% 2065
2019
Q3
$1.02M Buy
198,277
+2,330
+1% +$12K ﹤0.01% 2029
2019
Q2
$1.19M Buy
195,947
+15,555
+9% +$94.1K ﹤0.01% 1988
2019
Q1
$1.3M Buy
180,392
+5,364
+3% +$38.8K ﹤0.01% 1909
2018
Q4
$1.3M Buy
175,028
+64,940
+59% +$480K ﹤0.01% 1887
2018
Q3
$596K Sell
110,088
-6,872
-6% -$37.2K ﹤0.01% 2210
2018
Q2
$415K Buy
116,960
+17,005
+17% +$60.3K ﹤0.01% 2386
2018
Q1
$205K Sell
99,955
-1,155
-1% -$2.37K ﹤0.01% 2592
2017
Q4
$267K Sell
101,110
-7,474
-7% -$19.7K ﹤0.01% 2511
2017
Q3
$570K Buy
108,584
+3,970
+4% +$20.8K ﹤0.01% 2250
2017
Q2
$372K Buy
104,614
+2,650
+3% +$9.42K ﹤0.01% 2451
2017
Q1
$527K Buy
101,964
+2,703
+3% +$14K ﹤0.01% 2221
2016
Q4
$377K Buy
99,261
+6,607
+7% +$25.1K ﹤0.01% 2369
2016
Q3
$830K Buy
92,654
+3,819
+4% +$34.2K ﹤0.01% 1922
2016
Q2
$625K Buy
88,835
+11,802
+15% +$83K ﹤0.01% 2059
2016
Q1
$655K Buy
77,033
+4,255
+6% +$36.2K ﹤0.01% 2041
2015
Q4
$956K Buy
72,778
+7,130
+11% +$93.7K ﹤0.01% 1832
2015
Q3
$240K Sell
65,648
-12,358
-16% -$45.2K ﹤0.01% 2683
2015
Q2
$449K Buy
78,006
+980
+1% +$5.64K ﹤0.01% 2405
2015
Q1
$450K Buy
77,026
+10,900
+16% +$63.7K ﹤0.01% 2354
2014
Q4
$518K Buy
66,126
+11,605
+21% +$90.9K ﹤0.01% 2254
2014
Q3
$268K Sell
54,521
-1,300
-2% -$6.39K ﹤0.01% 2590
2014
Q2
$345K Sell
55,821
-12,673
-19% -$78.3K ﹤0.01% 2505
2014
Q1
$366K Sell
68,494
-620
-0.9% -$3.31K ﹤0.01% 2410
2013
Q4
$361K Sell
69,114
-2,400
-3% -$12.5K ﹤0.01% 2460
2013
Q3
$395K Sell
71,514
-411
-0.6% -$2.27K ﹤0.01% 2361
2013
Q2
$181K Buy
+71,925
New +$181K ﹤0.01% 3032